Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePratique

Hypertension in the elderly

New blood pressure targets and prescribing tips

Tessa Laubscher, Loren Regier and Shannon Stone
Canadian Family Physician May 2014; 60 (5) 453-456;
Tessa Laubscher
Assistant Professor of Academic Family Medicine at the University of Saskatchewan in Saskatoon.
MB ChB CCFP FCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loren Regier
Program Coordinator of the RxFiles Academic Detailing Program for Saskatoon Health Region.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: regierl@rxfiles.ca
Shannon Stone
Pharmacist for the RxFiles Academic Detailing Program.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • CFPlus
  • eLetters
  • Info & Metrics
  • PDF
Loading

Bruce M. is an 82-year-old patient with moderate dementia (Mini-Mental State Examination score of 12), recently admitted to long-term care following surgery for a hip fracture 6 weeks ago. Other relevant medical history includes coronary artery disease (myocardial infarction [MI] 10 years ago treated with angioplasty and stent), long-standing hypertension, stage 3 chronic kidney disease (estimated glomerular filtration rate of 40 mL/min), and benign prostatic hypertrophy. Medications include 10 mg of ramipril daily, 25 mg of hydrochlorothiazide daily, 50 mg of metoprolol twice daily, 10 mg of rosuvastatin daily, 81 mg of acetylsalicylic acid daily, 0.4 mg of controlled-release tamsulosin daily, 70 mg and 5600 IU of alendronate–vitamin D weekly, and 1000 mg of acetaminophen 3 times daily. The bisphosphonate–vitamin D pill and acetaminophen are the only new medications since his hip fracture.

The nursing staff report that Bruce appears to be light-headed and unsteady when he stands up to move with his walker. They are concerned that he will fall. Clinical data from the past week show blood pressure (BP) readings ranging from 130/84 to 118/60 mm Hg and a regular pulse of 54 to 70 beats/min. Apart from cognitive impairment and evidence of recent hip surgery, findings of his clinical examination are unremarkable, with no signs of heart failure and only a 5–mm Hg postural BP drop.

As the family physician providing ongoing care to Bruce, would you consider any changes in his medical management?

Bringing evidence to practice

Blood pressure targets in the elderly

  • Recent changes in the recommendations for BP targets in older adults have been the subject of considerable discussion. Variation among guidelines has resulted from evidence that aggressive BP lowering in older adults might lack benefit while increasing adverse event risk (Table 1).1–3 The Canadian Hypertension Education Program has proposed a revision of the recommendation for those older than 80 years of age with isolated systolic hypertension: In the very elderly (age 80 years and older), who do not have diabetes or target organ damage, the [systolic BP] threshold for initiating drug therapy is ≥ 160 mm Hg and the BP target is < 150 mm Hg (Grade C).4

  • One trial (Hypertension in the Very Elderly Trial) has looked specifically at those aged 80 and older (Table 2).5 Although guidelines differ somewhat, BP targets are more aggressive for those with diabetes (Table 3).4–9 Individualize BP targets in older adults based on their frailty, comorbidities, life expectancy, and tolerability to medications.

  • Diastolic BP is also important. Recent guidelines caution against lowering diastolic BP to below 60 or 65 mm Hg when isolated systolic hypertension and established coronary artery disease are present, owing to concerns about myocardial ischemia.4,10 Diastolic BP below 65 mm Hg has been associated with an increased risk of stroke and cardiovascular events.11

View this table:
  • View inline
  • View popup
Table 1.

Hypertension treat-to-target randomized controlled trials (mean age > 70 y)

View this table:
  • View inline
  • View popup
Table 2.

Hypertension trials in the very elderly (age ≥ 80 y)

View this table:
  • View inline
  • View popup
Table 3.

Comparison of guidelines for BP targets: BP targets in older adults should be individualized based on a person’s frailty, comorbid conditions, and tolerability of the medications and adverse effects. The optimal target for BP remains undetermined. Benefits of treatment including reduction in heart failure and death from stroke or any cause in people > 80 y (mean 84 y) have been demonstrated with a target SBP < 150 mm Hg.5

Pharmacotherapy considerations for hypertension in the elderly

  • β-Blockers are not necessarily indicated indefinitely following MI.12 Evidence is lacking to support use of β-blockers for more than 3 years after MI, unless there are other compelling indications (eg, heart failure, stable angina, atrial fibrillation).13 They are a less effective antihypertensive option in older adults. If a decision is made to discontinue a β-blocker, it is important to taper the dose gradually, by 25% to 50% every 1 to 2 weeks, to minimize withdrawal symptoms (eg, reflex tachycardia, angina, anxiety, and general malaise).

  • When combined with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), thiazide diuretics are often synergistic and lower doses are often effective.14 Many combination products (ACEI or ARB combined with thiazide diuretics) are available to lessen the pill burden for those who are stable on such 2-drug regimens.

  • Thiazide diuretics might lose their effectiveness in those with impaired renal function (creatinine clearance < 30 mL/min). Use in combination with furosemide is effective in those with a greater degree of chronic kidney disease.

  • Better trial evidence for benefit of thiazide diuretics has been shown with chlorthalidone and indapamide as opposed to hydrochlorothiazide.5,11,15 Chlorthalidone is about 1.5 to 2 times more potent at the same dose (in milligrams) as hydrochlorothiazide. Some would consider a switch to chlorthalidone; however, the availability of only a single scored 50-mg strength tablet is inconvenient if the lower 12.5-mg dose is needed.

  • Ramipril is often given at 10 mg daily as a result of the HOPE (Heart Outcomes Prevention Evaluation) trial.16 The HOPE trial compared 10 mg of ramipril daily at bedtime with placebo in a population at high cardiovascular risk (average age 55). This higher dose might be preferred if there is another compelling indication (eg, heart failure). However, a lower dose is more suitable for those experiencing falls, dizziness, or other possible adverse events.

  • Thiazides, ACEIs, ARBs, and calcium channel blockers are all reasonable options for older adults. All of these, and especially diuretics, can cause orthostatic hypotension. Caution is required with calcium channel blockers, as pedal edema is a common complaint, often unnecessarily treated with furosemide, leading to a “prescribing cascade.”

  • α-Blockers (also used for benign prostatic hypertrophy) might be particularly problematic in causing orthostatic hypotension.17,18 (See the RxFiles Q&A on Orthostatic Hypotension available from CFPlus.*)18

Nonhypertension-related options for those with recent history or risk of falls and fractures

  • Assess for and consider the deprescribing of other possible medications that can increase fall risk (eg, antipsychotics, sedatives, benign prostatic hypertrophy treatment, antihyperglycemics).19 Both the Beers and STOPP (Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions) screening criteria are useful in identifying potentially problematic medications in the elderly.20,21

  • Implement nondrug measures to decrease the risk of falling (eg, removing area rugs, keeping walking area free of obstacles, ensuring adequate lighting, providing assistive devices for walking and transferring).

  • Ensure adequate vitamin D supplementation (eg, 800 to 2000 IU daily).22

  • Ensure adequate total calcium intake (1200 mg elemental calcium daily) from diet and supplements.22

  • Consider the role of a bisphosphonate for fracture prevention in high-risk individuals.22

  • Consider if hip protectors might be indicated to reduce fracture risk.23,24

Back to our case

Metoprolol was tapered from 50 mg twice daily to 25 mg twice daily for 2 weeks, with plans for a further reduction to 12.5 mg twice daily after an additional 2 weeks. Bruce was monitored for any symptoms of withdrawal such as reflex tachycardia or angina.

Hydrochlorothiazide was reduced to 12.5 mg daily and ramipril was reduced to 5 mg daily, with plans to reassess and switch to a combination product after 4 to 8 weeks if his BP were stable. A goal is set to avoid symptoms of hypotension, such as light-headedness, while managing hypertension with a target BP of below 150/90 mm Hg.

Tamsulosin was continued because Bruce’s family perceived it to be valuable; however, if Bruce continues to have light-headedness, it might be discontinued.

Further relaxing of BP targets and reduction in antihypertensive medication use might be considered if Bruce continues to have symptoms of hypotension or adverse effects from antihypertensive medications. Patient safety, quality of life, life expectancy, time-to-benefit from therapy, and overall pill burden are valid considerations in contextualizing guideline recommendations in older adults with increasing frailty. It is important to be alert for, and avoid, a potential prescribing cascade where a drug is added to counteract or treat the side effect of another drug.

Footnotes

  • This article is eligible for Mainpro-M1 credits.

  • To earn credits, go to www.cfp.ca and click on the Mainpro link.

  • La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de mai 2014 à la page e254.

  • ↵* The RxFiles Q&A on Orthostatic Hypotension is available at www.cfp.ca. Go to the full text of the article online and click on CFPlus in the menu at the top right-hand side of the page.

  • Competing interests

    RxFiles and contributing authors do not have any commercial competing interests. RxFiles Academic Detailing Program is funded through a grant from Saskatchewan Health to Saskatoon Health Region; additional “not for profit; not for loss” revenue is obtained from sales of books and online subscriptions.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. JATOS Study Group
    . Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008;31(12):2115-27.
    OpenUrlCrossRefPubMed
  2. 2.
    1. Ogihara T,
    2. Saruta T,
    3. Rakugi H,
    4. Matsuoka H,
    5. Shimamoto K,
    6. Shimada K,
    7. et al
    . Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension study (VALISH). Hypertension 2010;56(2):196-202.
    OpenUrlCrossRef
  3. 3.↵
    1. Cushman WC,
    2. Evans GW,
    3. Byington RP,
    4. Goff DC Jr,
    5. Grimm RH Jr,
    6. Cutler JA,
    7. et al
    . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1575-85.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Canadian Hypertension Education Program
    . Recommendations for hypertension treatment. Markham, ON: Canadian Hypertension Education Program; 2014. Available from: www.hypertension.ca/images/CHEP_2014/2014_CompleteCHEPRecommendations_EN_HCP1009.pdf. Accessed 2014 Mar 11.
  5. 5.↵
    1. Beckett NS,
    2. Peters R,
    3. Fletcher AE,
    4. Staessen JA,
    5. Liu L,
    6. Dumitrascu D,
    7. et al
    . Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358(18):1887-98.
    OpenUrlCrossRefPubMed
  6. 6.
    1. Mancia G,
    2. Fagard R,
    3. Narkiewicz K,
    4. Redon J,
    5. Zanchetti A,
    6. Böhm M,
    7. et al
    . 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014;23(1):3-16.
    OpenUrlCrossRefPubMed
  7. 7.
    1. James PA,
    2. Oparil S,
    3. Carter BL,
    4. Cushman WC,
    5. Dennison-Himmelfarb C,
    6. Handler J,
    7. et al
    . 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507-20.
    OpenUrlCrossRefPubMed
  8. 8.
    1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee
    . Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013;37(Suppl 1):S1-212.
    OpenUrlPubMed
  9. 9.↵
    1. American Diabetes Association
    . Standards of medical care in diabetes—2014. Diabetes Care 2014;37(Suppl 1):S14-80.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Aronow WS,
    2. Fleg JL,
    3. Pepine CJ,
    4. Artinian NT,
    5. Bakris G,
    6. Brown AS,
    7. et al
    . ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens 2011;5(4):259-352.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. SHEP Cooperative Research Group
    . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265(24):3255-64.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Bangalore S,
    2. Steg G,
    3. Deedwania P,
    4. Crowley K,
    5. Eagle KA,
    6. Goto S,
    7. et al
    . β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308(13):1340-9.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Fihn SD,
    2. Gardin JM,
    3. Abrams J,
    4. Berra K,
    5. Blankenship JC,
    6. Dallas AP,
    7. et al
    . 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60(24):e44-164.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Flack JM,
    2. Cushman WC
    . Evidence for the efficacy of low-dose diuretic monotherapy. Am J Med 1996;101(Suppl 3A):53S-60S.
    OpenUrlPubMed
  15. 15.↵
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
    . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel block vs. diuretic. JAMA 2002;288(23):2981-97.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Yusuf S,
    2. Sleight P,
    3. Pogue J,
    4. Bosch J,
    5. Davies R,
    6. Dagenais G,
    7. et al
    . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) study. N Engl J Med 2000;342(3):145-53.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Poon IO,
    2. Braun U
    . High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 2005;30(2):173-8.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Lu L,
    2. Stone S,
    3. Regier L
    . Orthostatic hypotension: considerations for management Q&A. Saskatoon, SK: RxFiles; 2014. Available from: www.rxfiles.ca/rxfiles/uploads/documents/OrthoHypo-QandA.pdf. Accessed 2014 Mar 10.
  19. 19.↵
    1. Farrell B,
    2. Monahan A,
    3. Ingar N
    . Identifying and managing drug-related causes of common geriatric symptoms. Can Fam Physician 2014;60:147-53.
    OpenUrlFREE Full Text
  20. 20.↵
    1. American Geriatrics Society 2012 Beers Criteria Update Expert Panel
    . American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60(4):616-31. Epub 2012 Feb 29.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. O’Mahony D,
    2. Gallagher P,
    3. Ryan C,
    4. Byrne S,
    5. Hamilton H,
    6. Barry P,
    7. et al
    . STOPP & START criteria: a new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med 2010;1(1):45-51.
    OpenUrlCrossRef
  22. 22.↵
    1. Papaioannou A,
    2. Morin S,
    3. Cheung AM,
    4. Atkinson S,
    5. Brown JP,
    6. Feldman S,
    7. et al
    . 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182(17):1864-73.
    OpenUrlFREE Full Text
  23. 23.↵
    1. Canadian Agency for Drugs and Technologies in Health
    . Hip protectors in long-term care: a review of the comparative clinical and cost-effectiveness. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2010. Available from: www.cadth.ca/media/pdf/l0208_hip_protectors_ltc_final.pdf. Accessed 2014 Mar 10.
  24. 24.↵
    1. Gillespie WJ,
    2. Gillespie LD,
    3. Parker MJ
    . Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2010;(10):CD001255.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 60 (5)
Canadian Family Physician
Vol. 60, Issue 5
1 May 2014
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hypertension in the elderly
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hypertension in the elderly
Tessa Laubscher, Loren Regier, Shannon Stone
Canadian Family Physician May 2014, 60 (5) 453-456;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Hypertension in the elderly
Tessa Laubscher, Loren Regier, Shannon Stone
Canadian Family Physician May 2014, 60 (5) 453-456;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Bringing evidence to practice
    • Back to our case
    • Footnotes
    • References
  • Figures & Data
  • CFPlus
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • L’hypertension chez les aînés
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Pratique

  • Prise en charge du diabète de type 2 en soins primaires durant la pandémie de la COVID-19
  • Pneumothorax spontané chez l’enfant
  • Approche diagnostique et de prise en charge du trouble déficitaire de l’attention avec hyperactivité chez l’enfant
Show more Pratique

RxFiles

  • How to help patients navigate genitourinary syndrome of menopause
  • Clinical pearls for management of migraines
  • Perles cliniques sur la prise en charge des migraines
Show more RxFiles

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire